Sound Shore Management Inc CT boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 1.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 4,131,801 shares of the company’s stock after buying an additional 75,315 shares during the quarter. Elanco Animal Health makes up approximately 2.1% of Sound Shore Management Inc CT’s investment portfolio, making the stock its 27th biggest holding. Sound Shore Management Inc CT’s holdings in Elanco Animal Health were worth $51,276,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Venture Visionary Partners LLC acquired a new stake in shares of Elanco Animal Health during the 2nd quarter valued at about $45,000. Fifth Third Bancorp lifted its holdings in shares of Elanco Animal Health by 139.6% during the second quarter. Fifth Third Bancorp now owns 2,396 shares of the company’s stock valued at $47,000 after acquiring an additional 1,396 shares during the period. CKW Financial Group boosted its stake in shares of Elanco Animal Health by 60.0% in the 2nd quarter. CKW Financial Group now owns 2,400 shares of the company’s stock valued at $49,000 after purchasing an additional 900 shares in the last quarter. Eagle Bay Advisors LLC increased its position in shares of Elanco Animal Health by 4,040.0% during the 2nd quarter. Eagle Bay Advisors LLC now owns 2,691 shares of the company’s stock worth $53,000 after purchasing an additional 2,626 shares in the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in Elanco Animal Health by 689.3% in the third quarter. SRS Capital Advisors Inc. now owns 4,578 shares of the company’s stock valued at $57,000 after buying an additional 3,998 shares in the last quarter.
Insider Transactions at Elanco Animal Health
In other news, Director John P. Bilbrey bought 7,500 shares of the company’s stock in a transaction that occurred on Friday, November 11th. The shares were acquired at an average price of $13.24 per share, with a total value of $99,300.00. Following the transaction, the director now owns 41,722 shares in the company, valued at $552,399.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.40% of the stock is owned by insiders.
Analysts Set New Price Targets
Elanco Animal Health Stock Performance
ELAN stock opened at $12.83 on Wednesday. Elanco Animal Health Incorporated has a twelve month low of $11.18 and a twelve month high of $29.66. The company has a quick ratio of 1.12, a current ratio of 1.96 and a debt-to-equity ratio of 0.82. The company has a market cap of $6.08 billion, a P/E ratio of -53.96, a price-to-earnings-growth ratio of 6.63 and a beta of 0.90. The business’s fifty day moving average is $12.49 and its 200-day moving average is $14.50.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.04. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Elanco Animal Health had a negative net margin of 2.64% and a positive return on equity of 7.65%. Equities research analysts forecast that Elanco Animal Health Incorporated will post 1.04 EPS for the current year.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.